Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.

Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR.

J Am Coll Cardiol. 2013 Jan 15;61(2):148-52. doi: 10.1016/j.jacc.2012.09.042. Erratum in: J Am Coll Cardiol. 2014 Nov 4;64(18):1970.

3.

Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.

Bangalore S, Fayyad R, Hovingh GK, Laskey R, Vogt L, DeMicco DA, Waters DD; Treating to New Targets Steering Committee and Investigators..

Am J Cardiol. 2014 Jun 15;113(12):2018-20. doi: 10.1016/j.amjcard.2014.03.046. Review.

PMID:
24793673
4.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
5.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
6.

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.

PMID:
17910521
7.
8.

Safety of high-dose atorvastatin therapy.

Waters DD.

Am J Cardiol. 2005 Sep 5;96(5A):69F-75F. Review.

PMID:
16126026
9.

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ.

Am J Cardiol. 2010 Jan 1;105(1):69-76. doi: 10.1016/j.amjcard.2009.08.651. Review.

PMID:
20102893
10.
11.

Statin diabetogenicity: guidance for clinicians.

Ray K.

Cardiovasc Diabetol. 2013;12 Suppl 1:S3. doi: 10.1186/1475-2840-12-S1-S3. Review.

12.

Statins and new-onset diabetes.

Barylski M, Nikolic D, Banach M, Toth PP, Montalto G, Rizzo M.

Curr Pharm Des. 2014;20(22):3657-64. Review.

PMID:
24040871
13.

Is statin-induced diabetes clinically relevant? A comprehensive review of the literature.

Bell DS, DiNicolantonio JJ, O'Keefe JH.

Diabetes Obes Metab. 2014 Aug;16(8):689-94. doi: 10.1111/dom.12254. Review.

PMID:
24373206
14.

Use of statins and the incidence of type 2 diabetes mellitus.

Bernardi A, Rocha VZ, Faria-Neto JR.

Rev Assoc Med Bras (1992). 2015 Aug;61(4):375-80. doi: 10.1590/1806-9282.61.04.375. Review.

15.

[Statin treatment causes an increased risk of type 2 diabetes].

Solis AB, Pilemann-Lyberg S, G├Žde P.

Ugeskr Laeger. 2014 Feb 3;176(3):227-31. Review. Danish.

PMID:
24629749
16.

Statin-Associated Diabetes Mellitus: Review and Clinical Guide.

Backes JM, Kostoff MD, Gibson CA, Ruisinger JF.

South Med J. 2016 Mar;109(3):167-73. doi: 10.14423/SMJ.0000000000000423. Review.

PMID:
26954655
Items per page

Supplemental Content

Support Center